- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy | Clinical
FDA Grants Orphan Drug Designation to Novel CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
November 26, 2021
A novel chimeric antigen receptor T-cell agent will now be developed in the United States following an orphan drug designation granted by the FDA.
FDA Granted RMAT Designation to CTX110 for B-Cell Malignancies
November 23, 2021
To address an unmet medical need for agents to treat B-cell malignancies, the FDA has granted an RMAT designation to CTX110, a chimeric antigen receptor T-cell therapy.
Chavez Discusses Systemic Therapy Challenges for Patients With Relapsed/Refractory DLBCL After CAR T-Cell Therapy Treatment
November 15, 2021
Eleven months after a 43-year-old woman with diffuse large B-cell lymphoma completed chimeric antigen receptor T-cell therapy, she complained of fever, night sweats, and back pain.
Roundtable Discussion: Persky and Participants Review CAR T-Cell Therapy in DLBCL
October 31, 2021
Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.
New Option After Tisagenlecleucel for Patients With R/R LBCL Now in Development
October 20, 2021
Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.
New CAR T-Cell Therapy Appears Safe in B-Cell Malignancies
October 13, 2021
The CAR T-cell therapy may provide another therapy option for patients with large B-cell lymphoma.
FDA Halts Development of Select Allogeneic CAR T-Cell Therapies Due to Safety Concern
October 08, 2021
All clinical trials of allogeneic CAR T cells developed by Allogene Therapeutics, Inc have been halted by the FDA pending an investigation of a chromosomal abnormality event.
CAR T Offer New Treatment Option for Non-Hodgkin Lymphoma
October 08, 2021
Michael R. Bishop, MD, discusses chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.
New Data Solidify Benefit of Loncastuximab Tesirine for Relapsed/Refractory DLBCL
October 01, 2021
In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment?
September 24, 2021
Mehdi Hamadani, MD and Bertram Glass, MD recently debated on the role of allogeneic hematopoietic stem cell transplant for the treatment of aggressive B-cell lymphoma now that chimeric antigen receptor T cells have entered the landscape.